Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and ...

Forced vital capacity (FVC) declined from baseline to 1 year by 98.6 mL and 84.6 mL on average with the 18-mg and 9-mg doses of the drug, respectively, compared with a decline of 165.8 mL in the ...

Pulmonary fibrosis is a very serious disease, with a life prognosis of 3 to 5 years after ... May 21, 2025 0. 3. Diseases, Conditions, Syndromes. Pulmonary fibrosis has no cure. Could a ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Additional Trial Results . A rapid reduction was seen in 24-hour cough frequency at Week 2 with Haduvio, the first time point measured. A 50% reduction in 24-hour cough frequency at Week 6 vs ...

On June 3, 2025, the industry’s first proof-of-concept clinical validation of AI-driven drug discovery was published in Nature Medicine. Insilico Medicine and collaborators reported promising ...

CAMBRIDGE, Mass., June 3, 2025 /PRNewswire/ -- Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025.. Encouraging clinical data showed that ...

--Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in patients with idiopathic pulmonary ...